CHPA Statement Regarding Use of NSAIDs and COVID-19

“In recent days, news reports and social media posts have suggested an association between the use of NSAIDs, such as ibuprofen, and poorer outcomes following COVID-19 infection. Today, the U.S. Food and Drug Administration (FDA) posted a statement that the agency ‘is not aware of scientific evidence connecting the use of NSAIDs, like ibuprofen, to worsening COVID-19 symptoms’, and is investigating the issue. The U.S. Centers for Disease Control and Prevention (CDC) states, ‘there are no data suggesting an association between COVID-19 clinical outcomes and NSAID use’.

“The World Health Organization (WHO) also advises that there is ‘no known evidence’ that ibuprofen worsens symptoms of COVID-19, and ‘WHO does not recommend against the use of ibuprofen’.  Furthermore, the European Medicines Agency (EMA) issued a similar statement saying, ‘There is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID 19’. EMA went on to further say, ‘When starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options including paracetamol and NSAIDs’, and added, ‘In line with EU national treatment guidelines, patients and healthcare professionals can continue using NSAIDs (like ibuprofen) as per the approved product information’.

 "Over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) in the U.S. are indicated and labeled under the authority of the U.S. Food and Drug Administration (FDA) to temporarily reduce fever and relieve minor aches and pains. The Consumer Healthcare Products Association (CHPA) and FDA remind consumers to read the full Drug Facts Label on OTC medicines to determine safe and appropriate use of all OTC medicines and to report severe or persistent symptoms to their healthcare providers.” 


Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system more than $7, contributing a total of $146 billion in savings each year. CHPA is committed to empowering consumer self-care by preserving and expanding choice and availability of consumer healthcare products. 

Contact: Mike Tringale (